Skip to content

Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility

Percutaneous Revascularization in Infarction With Late Presentation and Absence of Viability: Effects on Left Ventricular Remodeling and Contractility

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05160311
Enrollment
70
Registered
2021-12-16
Start date
2021-08-01
Completion date
2024-07-01
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Dysfunction, Percutaneous Coronary Intervention, STEMI - ST Elevation Myocardial Infarction

Keywords

STEMI, myocardial viability, Late percutaneous coronary intervention, myocardial remodelling, Myocardial reperfusion

Brief summary

The purpose of this study is to evaluate whether late recanalization in patients with ST elevation myocardial infarction (STEMI) without Viability on Cardiovascular Magnetic Resonance Image (MRI) can reduce the reverse remodeling through the reduction of the End Systolic Volume (ESV) at 6 months.

Detailed description

The purpose of this study is to evaluate whether late recanalization in patients with ST elevation myocardial infarction (STEMI) without Viability on Cardiovascular Magnetic Resonance can reduce the reverse remodeling through the reduction of the End Systolic Volume (ESV) at 6 months and through the improvement in segmental contractility of infarcted related artery at MRI.

Interventions

DRUGOptimized Medical Treatment (OMT)

Optimized Medical Drug Treatment

DEVICEDrug Eluting Stent (DES) Coronary Angioplasty

Percutaneous Angioplasty with DES

Sponsors

Instituto Dante Pazzanese de Cardiologia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Patients who had underestimated STEMI with more than 24 hours up to 28 days referred by the Cross System (Central For Regulation of Health Services Supply) and the Campo Limpo Hospital (Co-participant Center) will be admitted sequentially for coronary angiography in the hemodynamics sector of the Instituto Dante Pazzanese de Cardiologia (IDPC) from August 2021 to February 2023.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. STEMI not reperfused between 24 hours and 28 days 2. MI-related artery with \> or = 50% 3. Segmental dysfunction in the artery related to infarction. 4. Technical feasibility for PCI recanalization 5. Absence of Myocardial Viability 3.3

Exclusion criteria

1. Age \> 80 years 2. \< 1 year life expectancy 3. Post MI Angina 4. Clinical Instability 5. Electrical Instability 6. Previous Infarction with segment disfunction 7. New York Heart Association (NYHA) class III or IV of heart failure. 8. Previous diagnosis of congestive heart failure or cardiomyopathy 9. Severe heart valve disease 10. Absence of segmental dysfunction in the artery related to infarction 11. Coronary angiography without obstructive lesions 12. Indication of myocardial revascularization surgery 13. Opted for clinical treatment for technical reasons 14. Serum creatinine concentration greater than 2.5 mg/dl 15. Pacemaker or Implantable Cardiodefibrillator (ICD) 16. Brain Clip Carriers 17. Patients with Cochlear Implants 18. Refusal to sign the Informed Consent Form (ICF). 19. Inability to maintain outpatient follow-up for 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Reverse myocardial remodeling after late recanalization in patients without viability6 monthsEvaluate reverse remodeling after late recanalization in patients without viability measuring End Systolic Volume (ESV) by MRI

Secondary

MeasureTime frameDescription
Assessement of Myocardial contractility6 monthsEvaluate the change of reverse LV remodeling after late recanalization assessed by MRI.
Evaluate Quality of Life6 monthsEvaluate change from baseline in patients Quality of life using Abbreviated World Health Organization Quality of Life (WHOQOL-BREF) questionnaire. The WHOQOL-Bref (Field Trial Version) produces a profile with four domain scores and two individually scored items about an individual's overall perception of quality of life and health. The four domain scores are scaled in a positive direction with higher scores indicating a higher quality of life. The possible raw score ranges for each domain are as follows: Physical Health=28, Psychological=24, Social Relationships=12, and Environment=32.
Acute MI Event6 monthsIncidence of Acute Myocardial Infarct.
Assessement of Left Ventricle Ejection Fraction (LVEF)6 monthsChange in LVEF measured by MRI The degree of LVEF recovery after a MI provides important prognostic information. Patients with no recovery in LVEF after MI are at high risk of sudden cardiac arrest events and death.
Cardiovascular Death6 monthsIncidence of Cardiovascular Death. Cardiac death is defined as any death in which a cardiac cause cannot be excluded. (This includes but is not limited to acute myocardial infarction, cardiac perforation/pericardial tamponade, arrhythmia or conduction abnormality, cerebrovascular accident within 30 days of the procedure or cerebrovascular accident suspected of being related to the procedure, death due to complication of the procedure, including bleeding, vascular repair, transfusion reaction, or bypass surgery).
Cardiovascular-Related Hospitalization6 monthsIncidence of New Cardiovascular related Hospitalization after discharge
Stroke Event6 monthsIncidence of Stroke Event Stroke is defined as the rapid onset of a new persistent neurologic deficit attributed to an obstruction in cerebral blood flow and/or cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection).
Unplanned revascularization (Ischemia Driven and Not Ischemia Driven)6 monthsIncidence of Unplanned Myocardial revascularization (Ischemia Driven and Not Ischemia Driven) after hospital discharge

Countries

Brazil

Contacts

Primary ContactBarbara Valente, MD
barbaravalente@hotmail.com5585988083444
Backup ContactPedro Farsky, MD, PhD
pedro.farsky@gmail.com5511991662309

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026